Cargando…

Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration

BACKGROUND: Mitomycin C (MMC) is an antitumor agent that is often administered intravesically to treat bladder cancer. Pharmacologically optimized studies have suggested varying methods to optimize delivery, with drug concentration and solution volume being the main drivers. However, these MMC conce...

Descripción completa

Detalles Bibliográficos
Autores principales: Myers, Alan L., Zhang, Yan-Ping, Kawedia, Jitesh D., Zhou, Ximin, Sobocinski, Stacey M., Metcalfe, Michael J., Kramer, Mark A., Dinney, Colin P. N., Kamat, Ashish M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427054/
https://www.ncbi.nlm.nih.gov/pubmed/28470465
http://dx.doi.org/10.1007/s40268-017-0183-y
_version_ 1783235588227334144
author Myers, Alan L.
Zhang, Yan-Ping
Kawedia, Jitesh D.
Zhou, Ximin
Sobocinski, Stacey M.
Metcalfe, Michael J.
Kramer, Mark A.
Dinney, Colin P. N.
Kamat, Ashish M.
author_facet Myers, Alan L.
Zhang, Yan-Ping
Kawedia, Jitesh D.
Zhou, Ximin
Sobocinski, Stacey M.
Metcalfe, Michael J.
Kramer, Mark A.
Dinney, Colin P. N.
Kamat, Ashish M.
author_sort Myers, Alan L.
collection PubMed
description BACKGROUND: Mitomycin C (MMC) is an antitumor agent that is often administered intravesically to treat bladder cancer. Pharmacologically optimized studies have suggested varying methods to optimize delivery, with drug concentration and solution volume being the main drivers. However, these MMC concentrations (e.g. 2.0 mg/mL) supersede its solubility threshold, raising major concerns of inferior drug delivery. OBJECTIVE: In this study, we seek to confirm that the pharmacologically optimized MMC concentrations are achievable in clinical practice through careful modifications of the solution preparation methods. METHODS: MMC admixtures (1.0 and 2.0 mg/mL) were prepared in normal saline using conventional and alternative compounding methods. Conventional methodology resulted in poorly soluble solutions, with many visible particulates and crystallates. However, special compounding methods, which included incubation of solutions at 50 °C for 50 min followed by storage at 37 °C, were sufficient to solubilize drug. Chemical degradation of MMC solutions was determined over 6 h using high-performance liquid chromatography (HPLC) analytics, while physical stability was tested in parallel. RESULTS: Immediately following the 50 min incubation, both MMC solutions exhibited approximately 5–7% drug degradation. Based on the measured concentrations and linear regression of degradation plots, additional storage of these solutions at 37 °C for 5 h retained chemical stability criterion (< 10% overall drug loss). No physical changes were observed in any solutions at any test time points. CONCLUSION: We recommend that the described alternative preparation methods may improve intravesicular delivery of MMC in this urological setting, and advise that clinicians employing these changes should closely monitor patients for MMC toxicities and pharmacodynamics (change in clinical outcomes) that result from the potential enhancement of MMC exposure in the bladder.
format Online
Article
Text
id pubmed-5427054
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-54270542017-05-25 Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration Myers, Alan L. Zhang, Yan-Ping Kawedia, Jitesh D. Zhou, Ximin Sobocinski, Stacey M. Metcalfe, Michael J. Kramer, Mark A. Dinney, Colin P. N. Kamat, Ashish M. Drugs R D Original Research Article BACKGROUND: Mitomycin C (MMC) is an antitumor agent that is often administered intravesically to treat bladder cancer. Pharmacologically optimized studies have suggested varying methods to optimize delivery, with drug concentration and solution volume being the main drivers. However, these MMC concentrations (e.g. 2.0 mg/mL) supersede its solubility threshold, raising major concerns of inferior drug delivery. OBJECTIVE: In this study, we seek to confirm that the pharmacologically optimized MMC concentrations are achievable in clinical practice through careful modifications of the solution preparation methods. METHODS: MMC admixtures (1.0 and 2.0 mg/mL) were prepared in normal saline using conventional and alternative compounding methods. Conventional methodology resulted in poorly soluble solutions, with many visible particulates and crystallates. However, special compounding methods, which included incubation of solutions at 50 °C for 50 min followed by storage at 37 °C, were sufficient to solubilize drug. Chemical degradation of MMC solutions was determined over 6 h using high-performance liquid chromatography (HPLC) analytics, while physical stability was tested in parallel. RESULTS: Immediately following the 50 min incubation, both MMC solutions exhibited approximately 5–7% drug degradation. Based on the measured concentrations and linear regression of degradation plots, additional storage of these solutions at 37 °C for 5 h retained chemical stability criterion (< 10% overall drug loss). No physical changes were observed in any solutions at any test time points. CONCLUSION: We recommend that the described alternative preparation methods may improve intravesicular delivery of MMC in this urological setting, and advise that clinicians employing these changes should closely monitor patients for MMC toxicities and pharmacodynamics (change in clinical outcomes) that result from the potential enhancement of MMC exposure in the bladder. Springer International Publishing 2017-05-03 2017-06 /pmc/articles/PMC5427054/ /pubmed/28470465 http://dx.doi.org/10.1007/s40268-017-0183-y Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research Article
Myers, Alan L.
Zhang, Yan-Ping
Kawedia, Jitesh D.
Zhou, Ximin
Sobocinski, Stacey M.
Metcalfe, Michael J.
Kramer, Mark A.
Dinney, Colin P. N.
Kamat, Ashish M.
Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration
title Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration
title_full Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration
title_fullStr Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration
title_full_unstemmed Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration
title_short Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration
title_sort solubilization and stability of mitomycin c solutions prepared for intravesical administration
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427054/
https://www.ncbi.nlm.nih.gov/pubmed/28470465
http://dx.doi.org/10.1007/s40268-017-0183-y
work_keys_str_mv AT myersalanl solubilizationandstabilityofmitomycincsolutionspreparedforintravesicaladministration
AT zhangyanping solubilizationandstabilityofmitomycincsolutionspreparedforintravesicaladministration
AT kawediajiteshd solubilizationandstabilityofmitomycincsolutionspreparedforintravesicaladministration
AT zhouximin solubilizationandstabilityofmitomycincsolutionspreparedforintravesicaladministration
AT sobocinskistaceym solubilizationandstabilityofmitomycincsolutionspreparedforintravesicaladministration
AT metcalfemichaelj solubilizationandstabilityofmitomycincsolutionspreparedforintravesicaladministration
AT kramermarka solubilizationandstabilityofmitomycincsolutionspreparedforintravesicaladministration
AT dinneycolinpn solubilizationandstabilityofmitomycincsolutionspreparedforintravesicaladministration
AT kamatashishm solubilizationandstabilityofmitomycincsolutionspreparedforintravesicaladministration